Roth Capital Partners initiated coverage of Allena Pharmaceuticals (NASDAQ: ALNA) with a “buy” rating and a $61 price target. The stock closed at $11.02 on March 29.Read More
Leerink resumed coverage of Ardelyx (NASDAQ:ARDX) with an “outperform” rating and $13 price target. The stock closed at $6.40 on Oct. 16.Read More
Fresenius Medical Care (FSE:FME; NYSE:FMS) has extended its exclusive licensing agreement with closely-held Interface Biologics for use of the Endexo technology in chronic dialysis systems to cover the acute dialysis market, including continuous renal replacement therapy.
Interface BiologicsInterface’s Endexo is a self-locating fluoro-oligomeric additive that results in a passive surface that reduces platelet adhesion and activation, protein adsorption and thrombus formation in medical devices, potentially reducing the use of drugs such as heparin.Read More